The brief

Analyst view

• Nerivio got FDA De Novo authorisation in May 2019; it is now cleared for acute and preventive use from age 8.
• Over one million US treatments; US insurance coverage reached about 130 million lives by February 2026.
• China's NMPA approved Nerivio for acute migraine in adults in August 2025, with partner Pier 88 Health.

Technical approach

As reported

Remote stimulation

Treat head pain from the arm

Pulses on the upper arm excite skin nerves there; the brain's pain-control centres respond by damping pain signals elsewhere, including migraine.

Smartphone control

Wearable run from an app

A wireless patch is controlled by a phone app that sets intensity and logs treatments, so patients use it at home at the onset of an attack.